The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, -44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n=59) and > 50 g group (n=11) than the < 30 g group (n=40) of the IPSS voiding subscore improvement (-3.76, -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.

Original languageEnglish
Pages (from-to)342-348
Number of pages7
JournalInternational Neurourology Journal
Volume20
Issue number4
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Korea
Androgens
Prostate
Prostatic Neoplasms
Lower Urinary Tract Symptoms
Therapeutics
Urodynamics
Retrospective Studies
Urine

Keywords

  • Androgen deprivation therapy
  • Prostate neoplasms
  • Prostate volume

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Urology

Cite this

@article{1bb24808b2c244e2b1e070b2e31a2a48,
title = "The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea",
abstract = "Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14{\%}) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, -44.12{\%}). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n=59) and > 50 g group (n=11) than the < 30 g group (n=40) of the IPSS voiding subscore improvement (-3.76, -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.",
keywords = "Androgen deprivation therapy, Prostate neoplasms, Prostate volume",
author = "Hoon Choi and Hong Chung and Park, {Jae Young} and Lee, {Jeong Gu} and Bae, {Jae Hyun}",
year = "2016",
month = "1",
day = "1",
doi = "10.5213/inj.1632628.314",
language = "English",
volume = "20",
pages = "342--348",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "4",

}

TY - JOUR

T1 - The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea

AU - Choi, Hoon

AU - Chung, Hong

AU - Park, Jae Young

AU - Lee, Jeong Gu

AU - Bae, Jae Hyun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, -44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n=59) and > 50 g group (n=11) than the < 30 g group (n=40) of the IPSS voiding subscore improvement (-3.76, -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.

AB - Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, -44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n=59) and > 50 g group (n=11) than the < 30 g group (n=40) of the IPSS voiding subscore improvement (-3.76, -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.

KW - Androgen deprivation therapy

KW - Prostate neoplasms

KW - Prostate volume

UR - http://www.scopus.com/inward/record.url?scp=85010224332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010224332&partnerID=8YFLogxK

U2 - 10.5213/inj.1632628.314

DO - 10.5213/inj.1632628.314

M3 - Article

AN - SCOPUS:85010224332

VL - 20

SP - 342

EP - 348

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 4

ER -